Your session is about to expire
← Back to Search
Dupilumab for Atopic Dermatitis
This trial is testing if Dupixent can improve eczema by using non-invasive imaging methods.
- Atopic Dermatitis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 4 trial • 188 Patients • NCT04033367
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Your skin condition is rated as moderate to severe on a scale of 0 to 4.You have already been treated with Dupilumab (REGN668/SAR231893) before.You have used TCS or TCI cream in the two weeks before the start of the study.You have a skin condition called atopic dermatitis that covers more than 10% of your body.
- Group 1: Dupixent
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the target enrolment size for this clinical trial?
"Affirmative. Clinicaltrials.gov details that this clinical study, which was initially posted on March 1st 2022, is actively recruiting potential participants. The goal is to secure 15 individuals from a single medical site for the trial."
To what extent is Dupilumab hazardous to human health?
"After careful assessment, the safety of Dupilumab was assigned a rating of 3 - based on its status as an approved Phase 4 treatment."
Is it still possible to be enrolled in this clinical investigation?
"According to the clinicaltrials.gov listing, this medical study is in need of patients and was initially published on March 1st 2022 with a subsequent update on February 22nd 2022."
Share this study with friends